PI3Kα-selective inhibitor BYL719 (Alpelisib) could downregulate mutant p53 with MYC-dependent expression, which is treated with Head and neck squamous cell carcinoma (HNSCC) 50. Here, TP53 is linked to head and neck squamous cell carcinoma.